Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74


Simvastatin-induced cognitive dysfunction: two case reports.

Suraweera C, de Silva V, Hanwella R.

J Med Case Rep. 2016 Apr 5;10:83. doi: 10.1186/s13256-016-0877-8.


Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans.

Hendrie HC, Hake A, Lane K, Purnell C, Unverzagt F, Smith-Gamble V, Murrell J, Ogunniyi A, Baiyewu O, Callahan C, Saykin A, Taylor S, Hall K, Gao S.

Ethn Dis. 2015 Aug 7;25(3):345-54. doi: 10.18865/ed.25.3.345.


Statins Reduces the Risk of Dementia in Patients with Late-Onset Depression: A Retrospective Cohort Study.

Yang YH, Teng HW, Lai YT, Li SY, Lin CC, Yang AC, Chan HL, Hsieh YH, Lin CF, Hsu FY, Liu CK, Liu WS.

PLoS One. 2015 Sep 18;10(9):e0137914. doi: 10.1371/journal.pone.0137914. eCollection 2015.


Cholesterol, statins, and dementia: what the cardiologist should know.

Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS.

Clin Cardiol. 2015 Apr;38(4):243-50. doi: 10.1002/clc.22361. Epub 2015 Apr 13. Review.


Statin use and cognitive function: population-based observational study with long-term follow-up.

Joosten H, Visser ST, van Eersel ME, Gansevoort RT, Bilo HJ, Slaets JP, Izaks GJ.

PLoS One. 2014 Dec 26;9(12):e115755. doi: 10.1371/journal.pone.0115755. eCollection 2014.


Cholesterol balance in prion diseases and Alzheimer's disease.

Hannaoui S, Shim SY, Cheng YC, Corda E, Gilch S.

Viruses. 2014 Nov 20;6(11):4505-35. doi: 10.3390/v6114505. Review.



Nicholson AM, Ferreira A.

Cogn Sci (Hauppauge). 2010 Jul 1;5(1):35-56.


HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.

Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC; Alzheimer's Disease Neuroimaging Initiative, Dufour R, Poirier J.

Mol Psychiatry. 2015 Jul;20(7):867-73. doi: 10.1038/mp.2014.81. Epub 2014 Jul 15.


Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors.

Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, Rakugi H, Morishita R.

Front Aging Neurosci. 2014 Apr 23;6:71. doi: 10.3389/fnagi.2014.00071. eCollection 2014. Review.


Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges.

Davis PR, Head E.

Front Pharmacol. 2014 Mar 21;5:47. doi: 10.3389/fphar.2014.00047. eCollection 2014. Review.


Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry.

Schilling JM, Cui W, Godoy JC, Risbrough VB, Niesman IR, Roth DM, Patel PM, Drummond JC, Patel HH, Zemljic-Harpf AE, Head BP.

Behav Brain Res. 2014 Jul 1;267:6-11. doi: 10.1016/j.bbr.2014.03.014. Epub 2014 Mar 19.


Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.

Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S.

BMC Med. 2014 Mar 22;12:51. doi: 10.1186/1741-7015-12-51. Review.


The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset.

Tschanz JT, Norton MC, Zandi PP, Lyketsos CG.

Int Rev Psychiatry. 2013 Dec;25(6):673-85. doi: 10.3109/09540261.2013.849663.


Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Barone E, Di Domenico F, Butterfield DA.

Biochem Pharmacol. 2014 Apr 15;88(4):605-16. doi: 10.1016/j.bcp.2013.10.030. Epub 2013 Nov 11. Review.


Cerebrospinal fluid and blood biomarkers in Alzheimer's disease.

Humpel C, Hochstrasser T.

World J Psychiatry. 2011 Dec 31;1(1):8-18. doi: 10.5498/wjp.v1.i1.8. Review.


The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation.

Barone E, Di Domenico F, Mancuso C, Butterfield DA.

Neurobiol Dis. 2014 Feb;62:144-59. doi: 10.1016/j.nbd.2013.09.018. Epub 2013 Oct 2. Review.


Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment.

Steenland K, Zhao L, Goldstein FC, Levey AI.

J Am Geriatr Soc. 2013 Sep;61(9):1449-55. doi: 10.1111/jgs.12414. Epub 2013 Sep 3.


Multiplex biomarkers in blood.

Gupta VB, Sundaram R, Martins RN.

Alzheimers Res Ther. 2013 Jun 25;5(3):31. doi: 10.1186/alzrt185. eCollection 2013. Review.


Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.

Zhang YY, Fan YC, Wang M, Wang D, Li XH.

Clin Interv Aging. 2013;8:103-10. doi: 10.2147/CIA.S40405. Epub 2013 Jan 31.


Dyslipidemia and the risk of Alzheimer's disease.

Reitz C.

Curr Atheroscler Rep. 2013 Mar;15(3):307. doi: 10.1007/s11883-012-0307-3. Review.

Items per page

Supplemental Content

Support Center